Dirk van West

Prof. Dr. Dirk van West


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2009 in European Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
DWDirk van West
Dirk van West
SCStephan Claes
Stephan Claes
DDDirk Deboutte
Dirk Deboutte

1 December 2008 in Journal of Affective Disorders
Verified
Journal Article
Closed access
DWDirk van West
Dirk van West
SCStephan Claes
Stephan Claes
JSJosé Sulon
José Sulon
DDDirk Deboutte
Dirk Deboutte

30 September 2016 in European Child & Adolescent Psychiatry
Verified
Journal Article
Open access
PDF file
ASA. Simons
A. Simons
FEFrancois Eyskens
Francois Eyskens
IGI. Glazemakers
I. Glazemakers
DWDirk van West
Dirk van West
Many patients who visit a centre for hereditary metabolic diseases remarkably also suffer from a child psychiatric disorder. Those child psychiatric disorders may be the first sign or manifestation of an underlying metabolic disorder. Lack of knowledge of metabolic disorders in child psychiatry may lead to diagnoses being missed. Patients therefore are also at risk for not accessing efficacious treatment and proper counselling. To search the literature for the co-occurrence of child psychiatric disorders, such as ADHD, autism, psychosis, learning disorders and eating disorders and metabolic disorders. A search of the literature was conducted by performing a broad search on PubMed, using the terms “ADHD and metabolic disorders”, “autism and metabolic disorders”, “psychosis and metabolic disorders”, “learning disorders and metabolic disorders”, and “eating disorders and metabolic disorders”. Based on inclusion criteria (concerning a clear psychiatric disorder and concerning a metabolic disorder) 4441 titles and 249 abstracts were screened and resulted in 71 relevant articles. This thorough literature search provides child and adolescent psychiatrists with an overview of metabolic disorders associated with child psychiatric symptoms, their main characteristics and recommendations for further investigations.

28 March 2017 in Trials
Verified
Journal Article
Open access
PDF file
AVAnnelies Verlaet
Annelies Verlaet
BCBerten Ceulemans
Berten Ceulemans
HVHelene Verhelst
Helene Verhelst
DWDirk van West
Dirk van West
TBTess De Bruyne
Tess De Bruyne
NHNina Hermans
Nina Hermans
Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is associated with serious adverse effects like arrhythmia. Evidence on the association of ADHD with immune and oxidant-antioxidant imbalances offers potential for antioxidant and/or immunomodulatory nutritional supplements as ADHD therapy. One small randomised trial in ADHD suggests, despite various limitations, therapeutic benefit from Pycnogenol®, a herbal, polyphenol-rich extract. This phase III trial is a 10-week, randomised, double-blind, placebo and active treatment controlled multicentre trial with three parallel treatment arms to compare the effect of Pycnogenol® to MPH and placebo on the behaviour of 144 paediatric ADHD and attention-deficit disorder (ADD) patients. Evaluations of behaviour (measured by the ADHD-Rating Scale (primary endpoint) and the Social-emotional Questionnaire (SEQ)), immunity (plasma cytokine and antibody levels, white blood cell counts and faecal microbial composition), oxidative stress (erythrocyte glutathione, plasma lipid-soluble vitamins and malondialdehyde and urinary 8-OHdG levels, as well as antioxidant enzyme activity and gene expression), serum zinc and neuropeptide Y level, urinary catecholamines and physical complaints (Physical Complaints Questionnaire) will be performed in week 10 and compared to baseline. Acceptability evaluations will be based on adherence, dropouts and reports of adverse events. Dietary habits will be taken into account. This trial takes into account comorbid behavioural and physical symptoms, as well as a broad range of innovative immune and oxidative biomarkers, expected to provide fundamental knowledge on ADHD aetiology and therapy. Research on microbiota in ADHD is novel. Moreover, the active control arm is rather unseen in research on nutritional supplements, but of great importance, as patients and parents are often concerned with the side effects of MPH. Clinicaltrials.gov number: NCT02700685 . Registered on 18 January 2016. EudraCT 2016-000215-32 . Registered on 4 October 2016.

1 August 2010 in Psychiatry Research
Verified
Journal Article
Closed access
DWDirk van West
Dirk van West
JDJurgen Del-Favero
Jurgen Del-Favero
DDDirk Deboutte
Dirk Deboutte
CBChristine Van Broeckhoven
Christine Van Broeckhoven
SCStephan Claes
Stephan Claes

1 January 2010
Verified
Journal Article
Closed access
JCJan Croonenberghs
Jan Croonenberghs
SGSarah Van Grieken
Sarah Van Grieken
AWAnnick Wauters
Annick Wauters
DWDirk van West
Dirk van West
LBLucas Brouw
Lucas Brouw
DDDirk Deboutte
Dirk Deboutte